Prestige Biologics (KOSDAQ:A334970) - Stock Price, News & Analysis

A334970 Stock Overview

Specializes in the development and production of biologic agents and biosimilars. More details

A334970 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Risk Analysis

Earnings have declined by 17.4% per year over past 5 years

Volatile share price over the past 3 months compared to the KR market

Does not have meaningful revenue (₩2B)

Shareholders have been diluted in the past year

Prestige Biologics Co., Ltd. Competitors

GC Cell

KOSDAQ:A144510

₩395.2b

Bioneer

KOSDAQ:A064550

₩522.7b

D&D Pharmatech

KOSDAQ:A347850

₩361.6b

ToolGen

KOSDAQ:A199800

₩310.2b

Price History & Performance

Summary of all time highs, changes and price drops for Prestige Biologics
Historical stock prices
Current Share Price	₩5,600.00
52 Week High	₩7,830.00
52 Week Low	₩3,850.00
Beta	1.04
11 Month Change	-23.18%
3 Month Change	-5.56%
1 Year Change	13.59%
33 Year Change	-50.00%
5 Year Change	n/a
Change since IPO	-60.84%

Recent updates

Shareholder Returns

	A334970	KR Biotechs	KR Market
7D	-0.2%	-4.0%	-0.7%
1Y	13.6%	23.9%	-4.1%

Return vs Industry: A334970 underperformed the KR Biotechs industry which returned 23.9% over the past year.

Return vs Market: A334970 exceeded the KR Market which returned -4.1% over the past year.

Price Volatility

Is A334970's price volatile compared to industry and market?
A334970 volatility
A334970 Average Weekly Movement	8.3%
Biotechs Industry Average Movement	8.0%
Market Average Movement	5.6%
10% most volatile stocks in KR Market	11.5%
10% least volatile stocks in KR Market	2.7%

Stable Share Price: A334970's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A334970's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

Founded	Employees	CEO	Website
2015	n/a	n/a	pbpharma.co.kr

Prestige Biologics Co., Ltd. specializes in the development and production of biologic agents and biosimilars. Its product candidates include Herceptin for breast and stomach cancer; Avastin for colon, lung, and ovarian cancers; Humira for arthritis; PBP1510 for pancreatic cancer; Denosumab for bone loss, osteoporosis; Aflibercept for macular edema and metastatic colorectal cancer; Eculizumab for atypical haemolytic uremic syndrome; Ipilimumab for metastatic melanoma; and PBP1710 for solid tumors. Prestige Biologics Co., Ltd.

Prestige Biologics Co., Ltd. Fundamentals Summary

How do Prestige Biologics's earnings and revenue compare to its market cap?
A334970 fundamental statistics
Market cap	₩435.09b
Earnings (TTM)	-₩29.37b
Revenue (TTM)	₩2.17b

199.9x

P/S Ratio

-14.8x

P/E Ratio

Is A334970 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A334970 income statement (TTM)
Revenue	₩2.17b
Cost of Revenue	₩11.01b
Gross Profit	-₩8.84b
Other Expenses	₩20.53b
Earnings	-₩29.37b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-379.42
Gross Margin	-407.72%
Net Profit Margin	-1,354.23%
Debt/Equity Ratio	241.3%

How did A334970 perform over the long term?

See historical performance and comparison

Prestige Biologics KOSDAQ:A334970 Stock Report